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Resumo A cistectomia radical e´ o tratamento standard do carcinoma urotelial
invasivo da bexiga, contudo, cerca de metade dos paciente apresentam
recidivas apo´s a cirurgia e necessidade de quimioterapia siste´mica. Pa-
cientes com tumores invasivos da bexiga com caracter´ısticas ideˆnticas
apresentam variac¸o˜es significativas na evoluc¸a˜o natural da doenc¸a e
resposta ao tratamento, reflectindo a composic¸a˜o heteroge´nea do tu-
mor e a necessidade de uma tratamento personalizado. A avaliac¸a˜o
pre´via da sensibilidade do tumor a` quimioterapia e´ especialmente im-
portante e justifica´vel em pacientes com elevado risco de apresentar
resisteˆncia ao tratamento. Neste projecto, este risco e´ avaliado atrave´s
da ana´lise da expressa˜o de marcadores moleculares tais como o CD147,
previamente associado a mau progno´stico e resisteˆncia a` cisplatina.
O principal objectivo deste projecto era estabelecer um modelo directo
de carcinoma urotelial invasivo da bexiga humano atrave´s de xenotrans-
plante em ratinhos imunodeficientes, caracterizar o modelo e avaliar a
sua viabilidade como plataforma para o estudo da sensibilidade e re-
sisteˆncia dos tumores a` quimioterapia.
Um dos 9 fragmentos transplantados cresceu como implante prima´rio
nos ratinhos, tendo sido transferido com sucesso para novos ani-
mais, onde desenvolveu tumor em 2 dos 3 animais transplantados.
A ana´lise histolo´gica e immuno-histoqu´ımica (CD147, p53, p63, ki-67
e CK20) do xenotransplante, mostrou haver preservac¸a˜o da morfologia
e feno´tipo do tumor prima´rio, pelo menos durante o estabelecimento
do xenotransplante.
Estes resultados preliminares suportam o valor deste modelo para en-
saios com fa´rmacos, pore´m, sa˜o necessa´rios estudos adicionais para
validar o modelo e determinar o perfil dos pacientes que podem bene-
ficiar desta abordagem.

Abstract Radical cystectomy is a standard treatment for invasive bladder cancer,
however, approximately half of the patients have disease recurrence af-
ter surgery and require systemic chemotherapy. Significant variations in
the natural history and responses to treatment of patients with invasive
bladder cancer are seen between tumors with identical features, reflect-
ing the heterogeneity of the constituent tumor cells and the necessity
of a personalized management approach. The assessment of tumor
sensitivity to chemotherapeutic drugs is especially important and jus-
tifiable for patients with higher risk of showing drug resistance. In
this project this risk was evaluated through the expression of molecular
markers, such as CD147, that have been associated with poor outcome
and cisplatin resistance.
With this project we aimed to establish an urothelial cancer xenograft
model in nude mice from a sample of invasive urothelial carcinoma,
characterize it, and assess the feasibility of this model for chemotherapy
sensitivity and resistance testing.
1 of 9 specimens has grown as primary implant in nude mice and the
xenograft generated was successfully transfered to other mice with a
take rate of 2 in 3. Histologic and immunohistochemical (CD147,p53,
p63, ki-67 and CK20) analysis showed that xenografts retain the mor-
phology and phenotype of the original tumor, at least during xenograft
establishment.
These preliminary results supports the value of this model for drug
testing, however future studies are required to validate the model and
determine the profile of the patients that may benefit for this approach.
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Chapter 1
Introduction
1.1 Principles of tumor biology
A fully evolved tumor is a population of abnormal cells characterized by temporally
unrestricted growth and the ability to grow in at least three different tissue compartments:
the original compartment, the mesenchyme of the primary site (tumor invasion), and a
distant mesenchyme (tumor metastasis) [16].
Tumorigenesis in humans is a multistep process involving genetic alterations that drive
the progressive transformation of normal cells into highly malignant derivates [37]. The
process through which normal cells evolve progressively to a neoplasic state results in spe-
cific lesions characteristic of the intermediate steps that can be identified by pathological
analysis of the organ sites [28]. However, tumors are more than insular masses of prolifer-
ating cancer cells, they are complex tissues composed of multiple distinct cell types that
participate in heterotypic interactions with one another. Normal cells, which form tumor-
associated stroma, are participants in tumorigenesis contributing to the development and
expression of certain abnormal abilities [38]. As the cancer progresses, the surrounding
microenvironment co-evolves into an activated state through continuous paracrine commu-
nication, thus creating a dynamic signaling circuitry that promotes cancer initiation and
growth, and ultimately leads to a fatal disease [86].
There are six main alterations in cells physiology that collectively enable tumor growth
and metastatic dissemination (fig.1.1): 1. self-sufficiency in growth signals; 2. insensitivity
to growth-inhibitory (antigrowth) signals; 3. evasion of programmed cell death (apoptosis);
4. limitless replicative potential; 5. sustained angiogenesis; 6. tissue invasion and metasta-
sis [37]. The timing and sequence of these hallmark events can vary widely between tumors
of the same type and within the same tumor, but ultimately, all these hallmark capabilities
will be reached [37].
Self sufficiency in growth signals is characterized by a greatly reduced dependence
on exogenous growth stimulation and sustains chronic proliferation [38]. Normal tissues
control the production and release of growth-promoting signals required to progress from
a quiescent to active state (cell growth and division cycle), thereby ensuring a homeostasis
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Figure 1.1: Acquired capabilities of cancer [37].
of cell number and thus maintenance of normal tissue architecture and function. Cancer
acquires the capability to sustain proliferative signaling in a number of alternative ways:
by the generation of their own growth signals, alteration of transcellular tranducers of
these signals (number and/or activity), or alteration of intracellular circuits that translate
those signals [37]. Alternatively, Cancer cells may send signals to stimulate normal cells
within the supporting tumor-associated stroma, which reciprocate by supplying the cancer
cells with various growth factors [6]. DNA sequencing analysis of cancer cell genomes have
revealed somatic mutations that predict constitutive activation of signaling circuits usually
triggered by activated growth receptors. Activating mutations afecting the stucture of
the B-Raf protein, resulting in constitutive signaling to mitogen-activated protein (MAP)
kinase pathway and mutations in the catalytic subunit of phosphoinositide 3-kinase (PI3-
kinase) isoforms, which serve to hyperactivate the PI3-kinase signaling circuitry, have been
detected in an array of tumor types [51, 19].
Insensitivity to antiproliferative signals permits the cancer cells to avoid quiescence or
postmitotic states [37]. Antiproliferative signals include both soluble growth inhibitors
and immobilized inhibitors embedded in the extracellular matrix and on the surface of
nearby cells [37]. Dozens of tumor suppressors genes that operate in various ways to
limit cell growth and proliferation have been discovered through their characteristic inac-
tivation in one or another form of animal or human cancer. The genes that encode RB
(retinoblastoma-associated) proteins are key regulators of circuits that govern the deci-
sions of cells to proliferate or, alternatively, activate senescence [38]. RB protein integrates
4
growth-inhibitory signals from diverse extracellular and intracellular sources and decides
whether or not a cell should proceed through its growth-and-division cycle or commit apop-
tosis [38]. Additionally, several mechanisms of cell-to-cell contact inhibition that ensure
normal tissue homeostasis may also be abrogated during the course of tumorigenesis. The
product NF2 gene, cell-surface adhesion molecules and LKB1 epithelial polarity protein
are some of the molecules involved in these mechanisms that may be altered in tumor cells
[38].
Programmed cell death by apoptosis serves as a natural barrier to cancer development
and the ability to evade apoptotic programs allows cancer cells to expand in number. The
apoptotic pathway comprises a complex arrangement of sensors, effectors and regulators
[66]. The sensors are responsible for monitoring the extracellular and intracellular environ-
ment for conditions of normality or abnormality such extracellular survival factors, death
signals, DNA damage and hypoxia [66]. Many signals that elicit apoptosis converge on
the mitochondria, which responds to pro-apoptotic signals by releasing cytochrome C and
ultimately activate intracellular proteases (caspases) that will execute the death program
[37]. The evasion to apoptosis during carcinogenesis is often acquired through mutation on
bcl-2 family of proteins that regulate the programmed cell death and mutations of p53, a
tumor suppressor protein [66]. The protein p53 receives inputs from stress and abnormality
sensors that function within the cell’s intracellular operating systems and can stop cell-
cycle progression until conditions have been normalized or trigger apoptosis, depending on
the context.
The limitless replicative potential results from the gain of the abilities discussed above
(growth signal autonomy, insensitivity to antigrowth signals and resistance to apoptosis).
Since successive replications leads to the loss of protective telomerases resulting in chro-
mosomal disarray and cell death, these processes alone do not ensure tumor growth [37].
However, upregulated expression of the enzyme telomerase, which adds telomeric DNA
repeats to chromosome ends, allows malignant cells to maintain telomere length above
a critical threshold and consequently unlimitless replication potential [18]. The presence
of telomerase activity is correlated with a resistance to induction of both senescence and
apoptosis.
Like normal tissues, tumors require sustenance in the form of nutrients and oxygen as
well as an ability to evacuate metabolic wastes and carbon dioxide. The tumor-associated
neovasculature, generated by the process of angiogenesis, addresses these needs and is
essential for a rapid clonal expansion of the malignant cells and to the development of a
macroscopic tumor [37]. Angiogenesis is controlled by a balance of pro- and anti-angiogenic
factors. Some of these angiogenic regulators are signaling proteins that bind to stimulatory
or inhibitory cell-surface receptors displayed by vascular endothelial cells. The prototypes
of angiogenesis inducers and inhibitors are vascular endothelial growth factor-A (VEGF-
A) and thrombospondin-1 (TSP-1), respectively [38]. Angiogenesis is induced during the
multistage development of invasive cancers. Once angiogenesis has been activated, tumors
exhibit diverse patterns of neovascularization [38]. VEGF gene expression can be upregu-
lated both by hypoxia and by oncogene signaling and have been implicated in sustaining
tumor angiogenesis during tumor development [38].
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Tissue invasion and metastasis depends on all of the other five acquired hallmark ca-
pabilities, but the initial ability to uncouple from the primary tumor mass depends on
the physical characteristics of the cells [37]. This step requires modulation of interactions
with neighboring cells and the extracellular matrix, and production of proteases to degrade
the extracellular matrix and basement membrane [37]. These alterations promote invasive
behavior and metastasis, and are often associated to cadherins downregulation and over-
expression of proteases like MMP2 and MMP9 [37]. The best characterized alteration
involves the downregulation or mutational inactivation of E-cadherin, a key cell-to-cell
adhesion molecule, in carcinoma cells [38].
1.2 Bladder cancer
1.2.1 Epidemiology
Bladder cancer is the 7th most common cancer worldwide, with an estimated 386,365
new cases (297,338 in men and 89,027 in women) and 150,165 deaths (112,255 in men and
37,910 in women) each year. [26]. Of the 1631 new cases of bladder cancer diagnosed in 2001
in Portugal, 46% invaded the muscularis propria and 15-30% of superficial bladder cancer
progress to muscle invasion, usually within 5 years [48, 17]. The incidence of urinary bladder
cancer increases with age and is considerably more common in males than in females, with
an worldwide ratio of 3.4:1. In general, the prevalence this tumor in developed countries
is approximately 6-times higher compared with that of developing countries [22].
The origin of bladder cancer is multifactorial, with tobacco smoking and occupational
exposure to aromatic amines being the principal risk factors. Other etiological factors in-
clude analgesic abuse and chronic cystitis [22]. The influence of environmental factors in
the development of bladder cancers may be explained by the exposure of the bladder ep-
ithelium to chemicals we ingest or their metabolites, especially when in high concentration
or for extended periods of time.
Bladder neoplasms can arise from any of the bladder layers, being broadly classified
as either epithelial or nonepithelial (mesenchymal), with over 95% being epithelial [89].
Epithelial tumors with differentiation toward normal urothelium are named urothelial or
transitional cell carcinoma. Other primary epithelial tumors include adenocarcinoma, squa-
mous cell carcinoma, and small-cell carcinoma, which comprise approximately 6, 2, and
less than 1% of bladder tumors, respectively [35]. Neoplasms derived from mesenchymal
tissue differentiate toward muscle, nerve, cartilage, fat, connective tissue and blood vessels.
1.2.2 Classification
The classification of urothelial neoplasms has been an area of significant controversy
and debate over the last decade, with several classification/staging systems been proposed
for these neoplasms. Pathological stage is the most important determinant of prognosis
and treatment for bladder cancer [13]. An ideal staging system should accurately reflect
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the natural history of cancer at this site, describe the total cancer burden, assess the
extent of spread at the time of diagnosis, and stratify patients into prognostic groups
for treatment planning. Adoption of an uniform staging system permits comparison of
therapeutic interventions among different institutions.
Until a few years ago, the 1973 World Health Organization (WHO) scheme appeared
to be the most widely recognized and utilized. In an attempt to provide a method of
categorization that more accurately reflects a tumor’s biologic behavior, and to estab-
lish greater uniformity in defining urothelial lesions, the WHO/International Society of
Urological Pathology (WHO/ISUP) issued a consensus statement in 1998 regarding the
classification of urothelial lesions.
Growth pattern
The growth pattern of the tumor may be determinated macroscopically or microscopi-
cally. There are four main patterns [78]:
(1) Papillary, in wich the tumor is growing into the lumen of the bladder;
(2) Infiltrating, in which it is growing into the wall of the bladder;
(3) Papillary and infiltrating, in which it is growing into the lumen and into the wall;
(4) Non-papillary and non-infiltrating, in which the tumor is confined to the surface,
i.e., in situ.
This information is particularly important because of its relationship to prognosis. Papil-
lary carcinomas have a much better prognosis than infiltrating carcinomas [78].
Histological grading
Several systems have been used to grade and classify bladder neoplasms. In 1972 the
World Health Organization (WHO) proposed a system of grading (1-3) based on the degree
of anaplasia of tumor cells (table1.1) [78, 35]. Grade 1 tumors have an orderly arrange-
ment of normal cells lining papillae and minimal architectural abnormalities, anaplasia,
or pleomorphism. Mitotic figures are rare or absent. Grade 3 tumors demonstrate ex-
treme nuclear abnormalities, disordered architecture, loss of polarity, and frequent mitotic
activity. Although the definitions of grade 1 and grade 3 tumors are explicit, grade 2 is
a diagnosis of exclusion. In the early 1990s, several factors emerged that resulted in the
need to reevaluate this approach. Efforts were made to formulate an evidence-based sys-
tem that would provide stricter definitions for bladder tumor grading and have a larger
effect on prognosis and clinical decision-making, leading to the publication of a consensus
classification system for urothelial neoplasms by the WHO and the International Society
of Urologic Pathologists (ISUP) in 1998 (table1.2) [23, 35]. The clinical significance of this
schema was validated by subsequent studies, and in 2004 it was accepted as the standard
classification schema [22]. According to this system, urothelial tumors can be divided in
infiltrating urothelial carcinomas (UC) and non-invasive urothelial neoplasias based on the
presence of tumor invasion into bladder wall, and classified as low-grade or high-grade
based upon the degree of nuclear anaplasia and architectural abnormalities [22]. It is clas-
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Table 1.1: 1973 WHO grading criteria
Grade 1 Tumors with the least degree of cellular anaplasia compatible
with diagnosis of malignancy
Grade 2 Histologic features between grades 1 and 3
Grade 3 Tumors with the most severe degrees of cellular anaplasia
sified as infiltrating, when invades beyond the basement membrane [22]. The non-invasive
urothelial neoplasias includes flat lesions with atypia, like carcinoma in situ, and papillary
neoplasm (low grade and high grade).
Pathological staging
Another criterion for assessing the behavior of a tumor is to determine the depth of
its infiltration into the bladder wall or adjacent tissue, also designated as staging. Tumors
that have not invaded into muscularis propria are described as superficial bladder cancers,
and includes noninvasive papillary urothelial carcinoma (pTa), carcinoma in situ (CIS)
(pTis), and tumor invading into the lamina propria (pT1) (figure1.2) [12]. Stage pT2 and
pT3 carcinomas are defined by tumor invasion into muscularis propria and into perivesical
soft tissue, respectively [12].
Figure 1.2: TNM staging based on anatomic extent of cancer.
The tumor-nodule-metastasis (TNM) classification is based on the anatomic extent of
cancer, being helpful to plan treatment, assess prognosis, evaluate results of treatment and
stratify patients for therapeutic studies [34].
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Table 1.2: 2004 WHO/1998 ISUP classification of urothelial tumors [22].
Infiltrating urothelial carcinoma
With squamous differentiation
With glandular differentiation
With trophoblastic differentiation
Nested
Microcystic
Micropapillary
Lymphoepithelioma-like
Lymphoma-like
Plasmacytoid
Sarcomatoid
Giant cell
Undifferentiated
Non-invasive urothelial neoplasias
Urothelial carcinoma in situ
Non-invasive papillary urothelial carcinoma, high grade
Non-invasive papillary urothelial carcinoma, low grade
Non-invasive papillary urothelial neoplasm of low malignant potential
Urothelial papilloma
Inverted urothelial papilloma
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The TNM system, originally described by denoix in 1952, is based on the premise
that the choice of treatment and the chance of survival are related to the extent of the
tumor at the primary site (T), the presence or absence of cancer cells in regional lymph
nodes (N), and the presence or absence of metastasis beyond the regional lymph nodes (M)
[34]. The first international TNM recommendations for the clinical stage classification of
cancers of the breast and larynx were published by the International Union Against Cancer
(UICC) in 1958 [34]. Between 1960 and 1967, 9 UICC brochures were published describing
proposals for the classification of tumors at 23 body sites. In 1968, these brochures were
combined, representing the First Edition of TNM. Over the years, variations in the rules of
classification of certain sites were introduced, but in 1982, the national TNM committees
agreed to formulate a single TNM classification. The Fourth Edition of TNM, coordinated
with the UICC and American Joint Committee on Cancer (AJCC) and representing the
achievement of a worldwide agreement for the staging of adult solid tumors was then
published [47].
The TNM staging may be clinical (cTNM) or pathological (pTNM). The first is based
on evidence acquired before treatment by physical examination, imaging, endoscopy or
biopsy, whereas the pathological classification is based on evidence acquired before treat-
ment, supplemented or modified by the additional evidence resulting from surgery and
pathological examination. The pathological assessment requires adequate resection of the
tumor (pT), removal of adequate number of regional nodes (pN), and microscopic exami-
nation to assess distant metastasis (pM) [33].
Table 1.3 describes the TNM classification of urinary bladder carcinomas. T is divided
into 4 major parts (T1-T4), expressing increasing size or spread of primary tumor, whereas
N and M comprises 2 categories each (0-1), indicating absence or presence of tumor. The
stage of the cancer is defined by the combination of the TNM categories.
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Table 1.3: TNM staging system for urinary bladder carcinomas, adapted from [22].
Primary Tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Noninvasive papillary tumor
Tis Carcinoma in situ
T1 Tumor invades lamina propria
T2 Tumor invades muscularis propria bladder wall
T2a Tumor invades superficial muscle (inner half)
T2b Tumor invades deep muscle (outer half)
T3 Tumor invades perivesical tissue
T3a Microscopically
T3b Macroscopically (extravesical mass)
T4 Tumor invades an adjacent organ
T4a Tumor invades prostate, uterus or vagina
T4a Tumor invades pelvic or abdominal wall
Regional Lymph Nodes (N)
NX Regional lymph node cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a simgle lymph node, 2cm or less in greatest dimension
N2 Metastasis in a simgle lymph node, > 2cm but not > 5cm in greatest
dimension, or multiple lymph node, none > 5cm in greatest dimention
N3 Metastasis in a lymph node > 5cm in greatest dimension
Distant Metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant Metastasis
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1.3 Muscle invasive bladder cancer
The majority of patients with bladder cancers are diagnosed with a superficial, low-
grade, and non-invasive disease. These patients are treated by local excision often followed
by intravesical infusion of adjuvant therapy. Despite these treatments approximately 70%
of patients with superficial disease have tumor recurrence with 10 to 20% ultimately pro-
gressing to invasive disease [17].
1.3.1 Cancer biology
In order to understand the biology of bladder cancer we need to have in consideration
the unique context of the organ where it arises. The urothelium is a highly specialized
epithelium, situated between the urine and the blood [56]. The normal urothelium acts as
a permeability barrier protecting the underlying tissues from the toxic urinary substances
and adjusting its surface area actively and reversibly during micturition cycles [81, 64].
Furthermore, the uroepithelium releases various mediators and neurotransmitters which
may allow the epithelium to transmit information about the state of the mucosa and
bladder lumen to the underlying nervous, connective and muscular tissue [4].
Histologically the urothelium is comprised of a single-cell type phenotypically distint
in the different cell layers attributed to the different degree of cellular differentiation [111].
When viewed in cross section, the urothelium is composed of umbrella, intermediate, and
basal cell layers [64, 56]. Umbrella cells are a single layer of highly differentiated and
polarized cells, whose morphology and size depends on the filling state of the bladder [56].
These cells are polyhedral, and often multinucleated cells, thought to be derived from the
intermediate cells via cell-cell fusion [64, 56]. The intermediate cells are often pyriform,
mono-nucleated, and connected to one another and to the underlying umbrella cells by
desmoses [53]. This cell population rapidly differentiates when the overlying umbrella cells
are lost or removed. Cells in the basal layer are the smallest in size and least differentiated,
and this is where the proliferative compartment and stem cells are believed to reside [62, 56].
These cells can differentiate to become intermediate cells whose layer thickness depends
on species [56].
In developed countries, more than 90% of bladder cancer are transitional cell carcinomas
of urothelial origin, followed by squamous cell carcinoma, adenocarcinoma and small cells
carcinoma [21].
The histology of invasive urothelial carcinoma has no specific features, it shows infil-
trating cohesive nests of cells with moderate to abundant amphophilic cytoplasm and large
hypercromatic nuclei [22]. The nucleus is typically pleomorphic and has irregular contours.
The nucleoli are highly variable in number and appearance, ranging from single or mul-
tiple of small size to large eosinophilic [22]. Mitotic figures are common, with numerous
abnormal forms. The stoma often contains lymphocytic infiltrate with a variable num-
ber of plasma cells. Neutrophils and eosinophils are rarely prominent. Foci of squamous
and glandular differentiation are also common. Divergent differentiation into squamous or
glandular cells is frequently associated with high grade and stage UC [11].
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1.3.2 Clinical features
The type and severity of clinical signs and symptoms of invasive UC depends on the
extend and location of the tumor. The most common presenting symptom is painless gross
hematuria that may be followed by clotting and painful micturition. These symptoms may
also be associated with frequency, as in case of large tumor, or irritative symptoms like
dysuria and urgency [22].
Direct cystoscopic examination visualization of the bladder and transurethral resection
(TUR) continues to be the gold standard in the diagnosis of patients presenting symptoms
of urothelial carcinoma [5]. The specimen obtained by TUR permits the assessment of
tumor histology, grade and depth of invasion. The determination of size, and the presence
of extravesical extension or invasion of adjacent organs should be performed in order to
stage the disease [22, 5]. The tumor grade and stage are the primary prognostic variables
critical for prediction of patient outcome and selection of appropriate therapy.
1.3.3 Bladder cancer biomarkers
Bladder cancers are a mixture of heterogeneous cell populations, and numerous factors
are likely to be involved in dictating their recurrence, progression, and the patient’s survival
[57]. Prognostic markers play a key role in clinical practice, distinguishing patients into
different risk groups and thus informing treatment strategies and aiding patient counselling.
A better understanding of the molecular mechanisms involved in carcinogenesis and
cancer progression has identified a large number of molecular markers of bladder cancer,
each of which have a potential diagnostic and prognostic value. To have clinical reve-
lance, they must add some predictive capacity beyond that offered by the conventional
and pathological paramenters.
To date, numerous potential markers have been identified by a variety of molecular
biology and genetic studies. Molecular markers such as Ki-67 and TP53 do appear to
have some promising correlations with bladder cancer development, agressiveness and pro-
gression. However, many of them have shown insufficient sensitivity and specificity in
predicting the prognosis of bladder cancer patients, in particular, the high-risk patient
groups that are at risk of progression and recurrence [57].
Emmprin
Extracellular matrix metalloproteinase inducer (emmprin) or CD147 is a highly glyco-
sylated transmembrane protein that belongs to the immunoglobulin superfamily [8]. Emm-
prin is a tumor cell derived matrix metalloproteinase (MMP) inducer that is expressed on
the tumor cell surface and stimulates nearby fibroblasts and endothelial cells to produce
MMP, facilitating invasion by cancer cells [7, 8]. In addition to induction of MMP produc-
tion, emmprin also mediates angiogenesis via stimulation of vascular endothelial growth
factor (VEGF), anchorage-independent growth and multidrug resistance in a hyaluronan-
dependent fashion [75, 116, 106]. Constitutive expression of emmprin at low levels exists
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in most cell types, where it is involved in physiologic processes, moreover its expression at
high levels occurs during remodeling processes such as inflammation, embryonic develop-
ment and wound healing [79].
Structure
Emmprin consists of a 185 amino acid (aa) extracellular region containing two im-
munoglobulin (ig) domains, a 24 aa residue transmembrane domain and a 39 aa cytoplas-
matic domain (fig.1.3) [8].
Figure 1.3: Scheme of emmprin molecule [31].
The single transmembrane sequence is completely conserved among species and the
presence of a charge acidic residue (glutamic acid) within the hydrophobic sequence of this
domain suggests that transmembrane associations with other membrane proteins are likely
to occur [76].
The extracellular region contains three N-linked glycosylation sites that are variably
glycosylated. The degree of glycosylation is regulated through interaction with caveolin-1
and determines emmprin activity and function [105]. Emmprin forms homo-oligomers in
a cis-dependent manner in the plasma membrane. This process is mediated by the N-
terminal Ig-like domain, that is essential and sufficient for oligomerization [117].
Function
To date, emmprin has been reported to induce several MMP, including collagenase
(MMP1), gelatinase A (MMP2), stromelysin (MMP3), gelatinase B (MMP9), membrane
type (MT) 1 MMP (MMP14) and MT2 MMP (MMP15) [94, 116]. In addition to produc-
tion of MMPs, emmprin also binds MMP1 and retains it in the cell surface, promoting the
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turnover of pericellular collagen [36].
The MMP-inducing function of emmprin in part involves the molecule acting as a
counter receptor for itself in the N-terminal Ig domain [104]. Emmprin also interacts with
integrins and caveolin-1. Over expression of caveolin-1 causes a decrease in clustering of
emmprin on the cell surface and decrease induction of MMP1, contributing to the onco-
suppressive effects of caveolin-1 [105]. Association with caveolin-1 also prevents formation
of highly glycosylated forms of emmprin, inhibiting emmprin aggregation and activity [105].
Role of emmprin in cancer
Immunochemistry analysis showed that emmprin expression is significantly upregulated
in bladder cancer when compared with normal urothelium [80]. Other studies identified
emmprin overexpression as an independent predictor of worse prognosis in patients with
bladder cancer, where it was significantly associated with poor patient survival and higher
recurrence risk (Fig.1.4) [90, 2, 112]. Emmprin overexpression was also correlated with
tumor stage, histologic grade, and lymph node status, suggesting that its expression might
be important for the development of malignant potential in bladder cancer [112]. There
are also evidences that the expression levels of emmprin in invasive urothelial cancer of the
bladder are higher than those in noninvasive tumors [90].
Figure 1.4: Overall survival of patients with urothelial carcinoma according to emmprin
expression [2].
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Emmprin might promote tumor invasion and metastasis through stimulation of MMPs
and VEGF synthesis. Additionally, it also induces chemoresistance via the production of
hyaluronan, and confers cancer cells resistance to anoikis [75, 116, 106, 115].
Emmprin in tumor cells stimulates fibroblasts, endothelial cells or cancer cells them-
selves, to secrete an increased amount of metalloproteinases (MMPs), which are responsible
for the degradation of the extracellular matrix facilitating tumor invasion and metastasis
[8]. A study showed that emmprin was the most frequently upregulated mRNA and pro-
tein in micrometastatic cells isolated from the bone marrow of cancer patients, indicating
a key role of emmprin in the processes of tumorigenesis and metastasis [58].
Hyaluronan is a very high molecular weight polysaccharide, composed of repeating
disaccharide units, and is associated with the pericellular matrix surrounding proliferating
and motile cells in normal and pathological systems, where it serves both structural and
signaling functions [108]. On tumor cells, the interaction of hyaluronan with receptors on
the surface induces anchorage-independent growth and plays a critical role in cell survival
and multidrug resistance, possibly by stimulating the PI3-kinase and MAP kinase cell
survival pathways [75].
Anoikis is a form of apoptosis induced by loss or alteration of cell-cell or cell-matrix
anchorage. This process was studied in breast carcinoma cells, where the expression of
high levels of emmprin were associated with higher viability and resistance to anoikis
[115]. However, there are no studies of the influence on emmprin expression in anoikis in
bladder cancer cells.
p53
The p53 gene and protein both play critical roles in regulation of the cell cycle, apop-
tosis, and DNA synthesis and repair, with mutations in p53 thought to be one of the key
central events in urothelial carcinogenesis [97, 24, 32]. Most mutations in P53 are missense
and induce conformational changes in the p53 protein, causing an increase in the protein
half-life, which is the basis of its nuclear accumulation that is detectable by immunohisto-
chemistry (IHC) [25]. Thus, nuclear overexpression generally correlates with inactivation
of P53.However, overexpression could also be the result of a physiological response to DNA
damage [68]. Both p53 mutations and p53 nuclear accumulation have been associated with
increased grade and stage of cancer, and poor clinical outcome [25].
p63
p63, a member of the p53 gene family located on chromosome 3q27–28, encodes mul-
tiple proteins that may either transactivate p53 responsive genes (TAp63) or act as a
dominant-negative factor toward p53 and p73 (δ Np63) [113]. p63 is highly expressed in
the basal or progenitor layers of many epithelial tissues, and it seems to play a key role in
growth-suppression and differentiation of transitional epithelium [114, 109]. It is suggested
that TAp63 isoform is required for initiation of epithelial stratification and maintains a
proliferative potential of basal cell, while δNp63 allows cells to respond to signals required
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for maturation. In a normal bladder, TAp63 is expressed in basal cells, whereas δNp63 is
absent or weakly expressed in these cells [82]. In bladder carcinomas, elevated expression
of δNp63 and decreased expression of TAp63 has been observed [82]. These results sug-
gest that δNp63 might contribute to progression of bladder carcinomas. The diminished
p63 expression in TCCs may represent the loss of differentiation-associated, and therefore,
growth-inhibitory p63 isoforms, which may be associated with tumor stage and grade [109].
Ki-67
Ki-67 is a nuclear protein expressed by proliferating cells and can be used as a measure
of biological aggressiveness of a malignancy [10]. Ki-67 is an established marker of cell
proliferation, that can be observed immunohistochemically, being present during the G1,
S, G2, and M stages of the cell cycle, but absent in resting cells (G0 phase) [10, 69].
In bladder TCC, increased Ki-67 expression is related to tumor grade and stage, and
was independently associated with cancer recurrence and survival after radical cystectomy
[69]. Ki-67 labelling index distinguishes low-grade from highgrade tumors. However, Ki-
67 immunostaining can be most useful for patients with organ-confined disease (pT3 N0)
undergoing cystectomy, where it is strongly associated with recurrence and bladder cancer-
specific death, possibly suggesting the need for additional therapy [32].
CK20
Cytokeratin 20 (CK20) is a marker for tumors of low stage and grade, and is expressed
in the umbrella cells of normal urothelium and reactive atypia, where it is detected by IHC
[77]. When CK20 expression in bladder tumors is limited to the umbrella and superficial
cells, tumours are typically of low grade with a mild disease course, while expression in
the entire urothelium in more than 10% of the tumour cells is associated with higher
tumour grade, and an increased risk of recurrence and progression [83, 14]. Aberrant
CK20 expression thus appears to signify more aggressive disease.
1.3.4 Management of muscle-invasive bladder cancer
Radical cystectomy is the standard procedure therapy for patients with muscle-invasive
urothelial carcinoma of the bladder [5]. This surgery consists of the removal of the blad-
der, prostate, seminal vesicles, and perivesical tissue in men, and removal of the bladder,
uterus, fallopian tubes, and anterior vaginal wall in women. Lymphadenectomy, as part
of definitive surgery, has become the standard care and plays a prognostic and possibly
therapeutic role in this disease [100, 42]. Bladder sparing regimens may also be appropriate
for patients who are medically unfit for surgery or seek an alternative [5].
Even with optimal surgical management, approximately 50% percent of patients with
muscle-invasive disease relapse and die of their disease. Most patients who recur after cys-
tectomy relapse with distant metastases and 30% have local recurrences [30]. The risk of
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recurrence and bladder cancer related death increases significantly with increasing patho-
logical tumor grade, nodal status, quality and extent of surgery performed and advancing
final pathological stage [96].
Cisplatin based combination chemotherapy regimens like MVAC (methotrexate, vin-
blastine, doxorubicin and cisplatin) or GC (gemcitabine and cisplatin) prolongs survival
and are considered the standard chemotherapeutic regimens for patients with invasive car-
cinoma of the urothelium [5]. Both combinations are equally effective, although GC is less
toxic. The overall response rate with these regimens ranges from 50 to 70%, with com-
plete responses seen in 15 to 20% of cases [102, 107]. Patients unfit for cisplatina based
chemotherapy may be palliated with carboplatin based regimen or single-agent taxane or
gemcitabine. Vinflunine is an option for second line therapy in patients progressing with
first line platinum based chemotherapy [5].
1.3.5 Chemotherapy for invasive bladder cancer
In patients with pT3-4 and/or N+M0 disease, 5-year survival after radical cystectomy
is only 25 to 35% at best [41]. Optimal therapy to muscle-invasive bladder cancer aims
to prevent local recurrence, decrease the probability of metastases and improve survival.
Current evidence shows that this goals are best achieved by combining cisplatin based
chemotherapy with high quality radical surgery.
MVAC was introduced in 1985 and became the first successful chemotherapy regimen
used for metastatic bladder cancer [101]. Overall response proportion were achieved in 72%
of patients, including complete responses in 36%. Because MVAC also produced significant
responses in the primary tumor, the regime was given to patients before cystectomy as neo-
adjuvant chemotherapy and after, as adjuvant chemotherapy for muscle invasive bladder
cancer [95].
Some randomized trials studying the role of the adjuvant therapy after cystectomy
suggest survival benefit from chemotherapy with significant improvement in 3-years disease-
free survival [103]. An adjuvant approach allows the selection of patients at highest risk for
surgical failure based on accurate pathological staging in the cystectomy specimen rather
than in transurethral biopsy. This selection avoids overtreating patients who are estimated
to have a reasonable outcome from surgery alone.
Although MVAC is the established chemotherapy regimen, significant toxicity limits
its operative use to the fittest patients. In patients with advanced or metastatic urothelial
carcinoma, the combination of gencitabin plus cisplatina have comparable response pro-
portions and similar overall long term survival when compared with MVAC but much less
toxicity [110]. Reasons for not treating with adjuvant chemotherapy include poor perfor-
mance status, frequent surgical complications, major comorbidities, psychological distress,
poor renal function, old age and patient refusal [41].
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1.4 Cisplatin
Cis-Diamminedichloroplatinum(II) (cisplatin or cis-DDP) is an inorganic complex formed
by an atom of platinum surrounded by chlorine and ammonia atoms in the cis position of
a horizontal plane (fig.1.5).
Figure 1.5: Cisplatin structure.
Cisplatin entered into clinical trials in the early 1970s and was found to have significant
antitumor activity against testicular cancer, lymphoma, squamous cell carcinoma of the
head and neck, ovarian cancer, and bladder cancer [46, 65, 45]. Because of its significant
therapeutic effect in these tumors and activity against a number of other solid tumors,
it became the most frequently used antitumor agent. Initially, it was used as a single
agent in patients with metastatic disease refractory to chemotherapy and, subsequently,
it was tested in nonrefractory disease. Cisplatin was also included in various combination
regimens and employed following the failure of other, more conventional chemotherapies.
1.4.1 Mechanism of action
Cisplatin enters the cell by diffusion or active transport. Once inside the cell, its chloride
ligands are replaced by water molecules generating a positively charged aquated species
that can react with nucleophilic sites on intracellular macromolecules to form protein, RNA
and DNA adducts [54]. Studies with Escherichia coli and eukaryotic cells deficient in DNA
repair, showed that DNA adducts are the key toxic lesions formed by cisplatin [59, 29]. The
reaction with DNA yields monofunctional adducts, intrastrand crosslinks and interstrand
crosslinks with the platinum atom coordinated to the N7 position of guanine or adenine
[20, 9, 119]. Adduct formation results in inhibition of DNA replication, RNA transcription,
arrest at the G2 phase of the cell cycle, and/or programmed cell death [93, 15, 98, 72].
1.4.2 Resistance
Reduced intracellular accumulation of cisplatin, which may arise because of decreased
uptake or increased efflux, is frequently observed in cisplatin resistant cells [3]. Another
mechanisms of resistance is associated with the inactivation of cisplatin by sulfur-containing
molecules mediated by the binding to glutathione molecules [71]. Cisplatin can be cova-
lently linked to glutathione and this complex can be transported out of the cell by an
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ATP-dependent pump [49]. Metallothioneins are a family of cysteine rich proteins in-
volved in Zn2+ homeostasis and in the detoxification of heavy metals such as cadmium.
Metallothioneins binds to cisplatin and may also affect sensitivity to this drug [85].
Alterations in the DNA repair status and in the expression of oncogenes (such as c-fos,
c-myc, H-ras, c-jun, and c-abl) and tumor suppressor genes (such as p53) have also been
implicated in the cellular resistance to cisplatin [54].
1.5 Gemcitabine
Gemcitabine (2’,2’-difluoro 2’-deoxycytidine, dFdC) is an analogue of cytosine arabi-
noside (Ara-C) from which it differs structurally due to its fluorine substituents on position
2’ of the furanose ring (Figure 1) [44].
Although ara-C and gemcitabine are structurally similar, there are major differences
in their antitumor activity. Ara-C is one of the most effective agents for the treatment of
adult acute myelogenous leukemia, but it does not show activity against solid tumors as
does gemcitabine [55, 73].
Currently, gemcitabine is indicated for the treatment of bladder cancer, advanced non-
small cell lung cancer, advanced pancreatic cancer, breast cancer and ovarian cancer.
Figure 1.6: Ara-C and Gemcitabine chemical structure.
1.5.1 Mechanism of action
Gemcitabine is a prodrug which requires cellular uptake and intracellular phosphory-
lation. After entering the cell through a membrane nucleoside transporter, gemcitabine
is phosphorylated to gemcitabine monophosphate by deoxycytidine kinase (dCK), which
is then converted to gemcitabine di- and triphosphate [39, 67]. These are the active drug
metabolites.
The cytotoxic effect of gemcitabine is attributed to a combination of the actions per-
formed by these two metabolites. The active metabolite, gemcitabine triphosphate, com-
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petes with the natural deoxycytidine 5-triphosphate (dCTP) for the incorporation into
the DNA strand. Once incorporated, an additional natural nucleoside is added, masking
gemcitabine and preventing DNA repair by base pair excision [87, 74]. Thereafter, the
DNA polymerases are unable to proceed, a process designated as ‘masked DNA chain
termination’, leading to growth inhibition or cell death.
The active diphosphate metabolite of gemcitabine also inhibits DNA synthesis indi-
rectly through inhibition of ribonucleotide reductase RR [43, 74]. This effect blocks the
de novo DNA synthesis pathway and self-potentiates gemcitabine activity by decreasing
intracellular concentrations of normal deoxynucleotides triphosphate (particularly dCTP).
Reduction in cellular dCTP results in increased gemcitabine nucleotide incorporation into
DNA and increased formation of active gemcitabine di- and triphosphates, since dCK
activity is down-regulated by high cellular dCTP levels [40, 73]. Other self-potentiating
mechanisms of gemcitabine include a decreased elimination of gemcitabine nucleotides by
direct inhibition of cytidine deaminase, an enzyme that inactivates gemcitabine [87].
Gemcitabine can also be incorporated into RNA and inhibit RNA synthesis. While
incorporation of gemcitabine metabolites into RNA are concentration dependent, the ex-
tent of RNA synthesis inhibition seems to be cell-specific [91]. Gemcitabine exhibits cell
phase specificity, being primarily active against cells undergoing DNA synthesis (S-phase)
and under certain conditions blocking the progression of cells through the G1/S phase
boundary.
1.6 Xenograftic model
In 1971, Povlsen and Rygaard demonstrated that nude mice could accept heterotrans-
plantations of human adenocarcinomas of the colon and rectum and that these tumors could
be transferred consecutively from mouse to mouse, producing adenocarcinomas identical
with the original tumor tissues [88]. Since that time, the heterotransplantation of various
human tumors into immunodepressed hosts has been used to generate tissue for the study
of the biology, morphology and biochemical characteristics of human tumors [63, 61].
Xenografts and genetically engineered mice models have been used as the front line in
predicting efficacy and finding toxicities for cancer chemotherapeutic agents before enter-
ing the clinic. While the development of genetically engineered mouse models has con-
tributed greatly towards understanding the process of carcinogenesis and target selection,
the xenograft models established by injecting cultured cancer cells subcutaneously in a
nude/SCID mice, have been more popular for drug screening purposes due to its faster,
low cost, and ease establishment and monitorization [84]. Orthotopic implantation of these
cell lines recapitulates some of the features of the cancers from which such cells were derived,
however many agents that show consistent and potent anticancer efficacy in xenografts,
fail in the clinical trials due to lack of efficacy [52]. This might be due to reliance of
xenografts on small numbers of homogeneous cell lines adapted to the artificial culture
conditions and acquisition of biological characteristics significantly different from the orig-
inal natural clone over serial passages in culture. On the other hand, the establishment
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of direct xenografts of human cancers allows the transplantation of all cellular fractions
of the tumor, maintaining the original cell heterogeneity, tumor phenotype and malignant
potential. This approach has demonstrated superior correlation of chemosensitivity and
specificity data for individualized therapy [84]. Studies where intact tissue from the pa-
tient was transplanted into the mice have shown the excellent patient response prediction
rates of 90% and 97% for chemosensitivity and chemoresistance, respectively [27]. In het-
erotransplants the crucial interplay of stroma-neoplasic components is recapitulated in a
greater extent, contributing to better replication of pharmacogenomic profiles, histology,
chromosome complement, antigen expression, and gene expression of human tumors, which
accounts for their better predictive value as compared to cell line based xenografts. These
models may also be used for molecular and histopathologic studies in order to identify key
molecular markers involved in tumor response to chemotherapy.
However, there is also criticism associated with this model, related to the unrealistic
growing conditions of the local environment, that results on rare development of metastasis,
increased responsiveness to treatments and expression of different cell surface molecules
[50].
The use of direct xenografting of human cancers allows the transplantation of all cellular
fractions of the tumor, avoiding the clonal selection. Prior studies used different xenograft
models to study the bladder carcinoma [60, 92, 1]. These models may provide a unique
platform to test therapeutic approaches directed toward these cancers.
1.7 Aims of the project
Unpredictable outcomes from empiric therapy in patients with the same tumor type
and stage is a widely recognized and frustrating problem for patients, their caregivers, and
medical professionals. This is the case of invasive urothelial bladder cancer. Variations
in the natural history and responses to treatment are seen between tumors with identical
features, reflecting the heterogeneity of the constituent tumor cells. There has been a
long-standing hope that new markers and approaches could be used to optimize therapy
for each patient. To do that, we need to develop effective drug testing models, especially
for invasive bladder tumors with higher risk of being chemo resistant.
The first goal of this project is to develop a direct xenograft model of invasive urothelial
bladder carcinoma as a platform to predict tumoral sensitivity and resistance to cisplatin
and gemcitabine in vivo. This study will be started at the time of patient cystectomy
and have results in time to start the patient’s chemotherapeutic regimen, if necessary.
With the development of this model, we aim to select the best cancer treatment based
on responsiveness of individual tumors and have the possibility of tailor treatment to
individual patients—using effective agents while sparing unnecessary ones. The assessment
of tumor sensitivity to chemotherapeutic drugs will be especially useful and justifiable for
patients with higher risk of showing drug resistance. This risk will be evaluated through
the expression of molecular markers, such as CD147, that have been associated with poor
outcome and cisplatin resistance in previous studies.
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The reproducibility of the model and maintenance of the phenotype of the original
tumor will be assessed to guarantee the utility and validity of the model. This evaluation
will be done through the analysis of the degree to which the mouse xenografts and pa-
tients’ tumor correlate with each other in terms of histologic type and grade, expression of
molecular markers of aggressiveness such as CD147, Ki-67, p53, p63 and Ck20.
The final goal of this project is to identify the profile of the patients that would ben-
efit from this kind of drug testing and molecular markers associated with sensitivity or
resistance to the main chemotherapeutic drugs used to treat invasive urothelial bladder
carcinoma. We attempted to prospectively select individualized chemotherapy for patients
based on the expression of tumor markers and in vivo assessment of drug sensitivity and
resistance using xenografts established from fresh tumor samples.
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Chapter 2
Methods
2.1 Patient selection
The study consists of developing a direct invasive urothelial carcinoma xenograft model
as a platform for predict tumor response to cisplatin and gemcitabine chemotherapy. Figure
2.1 shows a schematic representation of the study design.
Figure 2.1: Schematic representation of the study design.
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The patient selected to collect the sample for xenograft establishment met the fol-
lowing inclusion criteria: invasive urothelial carcinoma confirmed by histologic analysis,
overexpression of emmprin, and therapeutic cystectomy with no previous neoadjuvant or
adjuvant chemotherapy. Tumor sample for transplantation was obtained directly from the
removed bladder and placed in RPMI medium with 1 % penicillin/streptomycin. Part of
the sample was fixed in formalin for histologic and immunohistochemical analysis.
2.2 Animals
Immunodeficient mice bearing the nu/nu gene (strain: N:NIH(s) II-nu/nu) where ob-
tained from the Animal Experimental Unit at IPATIMUP. These mice are characterized
by thymic hypoplasia, depletion of T and B lymphocytes of both T-cell zones of lymph
nodes and the spleen and poor development of hair. We used 9 males, 6 weeks old and a
median weight of 17,6g.
2.3 Xenotransplant of tumor tissue
The tumor sample was cut into 1 − 2mm3 fragments and individual pieces of tumor
were implanted subcutaneously (s.c.) through small horizontal incisions in the scapular
regions of 9 anesthetized nude mice (P0 generation). The animals were anesthetized using
isoflurane according to the manufacturer’s instructions.
Following transplantation of tumor fragments, all mice were observed weekly. Tumor
growth was assessed twice a week by measuring length(d1), width(d2) and height(d3) with
caliper, and estimated using the following formula:
TumorV olume =
pi
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× d1 × d2 × d3 (2.1)
Tumor grwoth rate is characterized by the tumor volume doubling time (DT) which is
the time period when V2 = 2V1 [70], and will be calculated using the following formula:
DT = (t2 − t1)ln2/ln(V2/V1) (2.2)
2.4 Established cell line
During the development of direct xenografts of invasive urothelial carcinoma, an es-
tablished cell line of urothelial carcinoma overexpressing emmprin was used to produce a
tumor model in vivo. The cells grown in monolayer culture were harvested during the ex-
ponential growth phase using trypsin and suspended in medium plus. After quantification,
the cells were re-suspended in medium without serum at a concentration of 1 × 108cells
per mL of medium. Subcutaneous inoculation of the cells was done using 0, 1mL of the
cell suspension (1 × 107).
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Monitorization and tumor volume assessment was carried out as described for the trans-
planted mice.
2.5 In vivo growth inhibition studies
Tumors were allowed to grow to a size of 1.5cm3 at which point were harvested, divided,
and transplanted to another mice (P1 generation). After second growth passage, tumors
were excised and propagated to cohorts of >15 mice, which constituted the treatment
cohort (P2 generation).
Tumors from P2 generation cohort were allowed to grow until reaching 200mm3, at
which time they were uniformly distributed by size in the following groups: control injected
with control vehicle, 0, 2mL i.p. weekly for 5weeks (n=X), T1 injected with cisplatin,
3mg/kg i.p. weekly for 5 weeks (n=X) and T2 injected with gemcitabine, 20mg/kg i.p.
weekly for 4 weeks (n=X). All mice were weighted and monitored for signs of toxicity, two
times per week. Tumor size was evaluated twice a week by caliper measurements using
the formula presented above. Relative tumor growth inhibition was calculated by relative
tumor growth of treated mice, divided by relative tumor growth of control mice (T/C)
since the initiation of therapy. The human end point criteria considered was weight loss >
30 % or debilitation.
The histology and immunohistochemistry of the original tumor and the tumors de-
veloped by the nude mice will be analyzed to characterize the tumors and evaluate the
maintenance of the primary tumor phenotype.
2.6 Immunohistochemical analysis
Formalin-fixed, paraffin-embedded (FFPE) tissue sections (3 µm) were tested with
primary antibodies against CD147, p53, p63 Ki-67 and CK20 using polymer-HRP detec-
tion method (Power vision). Table ?? lists all antibodies, dilutions, incubation times and
antigen-retrieval methods used. The sections were initially dewaxed in xylene and rehy-
drated in graded alcohols. Heat-induced epitope retrieval using citrate buffer was carried
out according antibody manufacturer’s instructions. Endogenous peroxidase activity was
inhibited by immersing sections in H2O2(0.6 %) in distilled water for 20 min. Sections
were rinsed in PBS-Tween prior to incubation with bovine serum albumin solution (20
min) to inhibit non-specific binding. PBS was subsequently used to wash sections between
stages. Sections were then incubated with the primary antibodies against CD147, p53, p63
Ki-67 and CK20. The bound primary antibody was detected by the addition of secondary
antibody conjugated with horseradish peroxidase polymer (Power Vision poly-HRP-anti
Ms/Rb/R IgG) for 30 minutes and DAB substrate for 7minutes. Then, the slides were
counterstained with hematoxylin and mounted. Positive and negative controls was run
simultaneously with tumor specimens. The staining patterns were assessed by two inde-
pendent observers (one of them an histopathologist) using standard light microscopy.
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Table 2.1: Overview of the antibodies used and tissue processing details.
Primary
Clone Source Dilution
Antigen
Incubation
antibody retrieval
CD147 HIM6
Acris Antibodies
1:100
Citrate,
60min/room temp
(AM08346PU-N) pH 6.0, 20min
P53 DO-7
Dako
1:100
Citrate,
Overnight/ 4oC
(M 7001) pH 6.0, 20min
P63 4A4
NeoMarkers
1:250
Citrate,
60min/room temp
(MS-108-P1) pH 6.0, 20min
Ki-67 DO-7
Dako
1:300
Citrate,
Overnight/ 4oC
(M 7240) pH 6.0, 20min
CK20 Ks20.8
Novocastra
1:250
Citrate,
Overnight/4oC
(NCL-CK20) pH 6.0, 20min
2.7 Histologic analysis
Tissue from the tumors and mice organs was fixed in 10 % phosphatebuffered formalin,
embedded in paraffin, serially sectioned at 4 µm, and were stained with hematoxylin-eosin
(H&E) for histological examination. The histologic type, degree of differentiation, nuclear
aplasia and extension of invasion were registered for each tumor sample.
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Chapter 3
Results
3.1 Pathologic features of the selected patient
The patient was a 69-year-old man with muscle invasive bladder cancer and was sub-
mitted to radical cystectomy with ilio-obturator lymph node dissection and uretero-ileal
anastomosis according to the Bricker technique. The pathologic analysis revealed a uni-
focal solid nodular tumor (3x2cm) with surface ulceration located in the posterior wall of
the bladder and diffuse carcinoma in situ. The histology showed a high grade urothelial
carcinoma with muscularis propria and perivesical fat invasion (pT3a). There was also
lymphovascular space invasion, but the lymph nodes (6) as well as the surgical margins
were tumor free. In addition to the bladder carcinoma, foci of high grade prostatic in-
traepithelial neoplasia and in situ urothelial carcinoma in the prostatic urethra were also
present.
Figure 3.1: Radical cystectomy specimen showing an ulcerated lesion in the posterior wall
of the urinary bladder.
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3.2 Establishment of Xenografts
To date, 1 of 9 specimens has grown as primary implant in nude mice (11%, 1/9) as
illustrated in the figure 3.2. At 6 weeks following transplantation one mouse (1a) was
sacrificed to access if there was tumor growth in any part of the body. All organs were
analyzed histologically and there was no evidence of tumor metastasis.
Figure 3.2: Schematic representation of mice evolution after tumor implantation. Tumor
growth was seen in one mouse (1b) out of 9, and was excised at 18weeks after xetransplan-
tation. This tumor was cut into fragments and implanted in 3 new mice (2a-c). The fluid
of the cyst developed with the tumor was also removed and injected (0, 5ml) s.c. in 2 mice
(2d and 2e). In the second passage, tumor growth was registered in 2 of the 3 mice, one
of them (2c) was excised and transplanted to new mice (treatment group). After tumor
excision, mouse 1b stayed alive for another 11 weeks, at that time, it was sacrificed due
to severe weight loss (30%). The red cross represents euthanized mice. One mouse was
sacrificed at 6 weeks to access if there was tumor growth in any part of the body. The
other 5 mice were euthanized after showing severe weight loss.
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The weight of the mice during the first part of the experience was similar between them
and stable, however, some mice started to lose weight after 5 months as represented in the
figure 3.3. Five recipient mice (1c, 1d, 1e, 1f and 1g) were euthanized after developing
cachexia (at 20, 23 and 26 weeks) with weight losses above 30% and reduced mobility.
Necropsy was performed on all euthanized animals. The histological analysis to the mice
organs showed no evidence of tumor metastasis and the cause of weight loss remained
unknown for four of them. The mouse sacrificed at 20 weeks (1c) showed hydronephrosis
caused by a bladder stone. However, the reason for calculus formation remain unexplained.
Figure 3.3: Weight variation of the mice six months after xenotransplant.
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3.2.1 Tumor growth
For the first week following implantation, a small bump was visible where the tumor was
inserted and then it disappeared. At 13 weeks (3 months) after transplant, a mass began
to appear at the site of implantation in one (mouse1b) of the 9 nude mice xenografted.
The xenograft had a lag period of 13 weeks before initial take was registered and
achieved the exponential growth phase after the 18th week (see figure 3.4a). Over the
period of 5 weeks, the tumor progressively grew to approximately 18mm in diameter (about
1, 5cm3). The tumor volume doubling time was approximately 6 days. The xenograft
grew as a solid subcutaneous tumor containing a fluid-filled sac. At the time of tumor
excision no macroscopic evidence of local invasion was seen. The mouse bearing the tumor
xenograft (1b) was sacrificed 11 weeks after tumor excision due to severe weight loss (30%).
(Histologic analysis will be done in the next weeks..)
After excision, the human tumor xenograft was cut into fragments and implanted in 3
new mice (2a, 2b and 2c). The fluid of the cyst developed with the tumor was also removed
and injected (0, 5ml) s.c. in 2 mice (2d and 2e). Tumor growth was seen in 2 (2d and 2c)
of the 3 mice implanted at 5 and 9 weeks following transplantation, respectively. After
8 weeks, the tumor of the mouse 2c had reached approximately 2, 5cm3 and was excised
and passed to 12 mice (P2). The tumor developed was a solid subcutaneous tumor with
no visible invasion of adjacent tissues. Figure 3.5a shows the tumor growth over the time.
The tumor doubling time was approximately 8 days. The growth rate was constant over
the time, with no exponential phase.
Tumor growth of the mouse 2b is represented in the figure 3.5b (green line), together
with the tumor growth curves of 2a and 1b. This chart allows the comparison between
the tumor growth rates of the P0 and P1 xenografts. This graphic shows a clear difference
among the growth rate in the first and second passages. The xenograft P0 grew faster than
the tumors P1, as suggested by the mean doubling time (6 and 8 days, respectively). To
date, the growth rate of the tumor 2b is quite similar to the 2a, but the complete analysis
of the growth pattern will only be possible when the tumor has reached the same level as
the other two.
The two mice injected with the fluid provender from the cyst of the first xenograft did
not showed any evidence of tumor growth until this moment.
The injection of 1.5×106 MCR cell suspension in the subcutaneous space did not result
in tumor establishment, so far (12 weeks after inoculation).
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(a) Mouse 1b bearing a subcutaneous tumor devel-
oped after engraftment of human invasive urothelial
bladder cancer (p0). Picture taken at the day tumor
excision.
(b) Tumor growth curve of the P0 xenograft. Tumor
take was registered 13 weeks after implantation.
Figure 3.4: Xenograft Establishment.
(a) Growth of human bladder tumor in nude mice,
second passage. Tumor take was registered 5 weeks
after implantation.
(b) Tumor growth: comparison between first (1b) and
second passages (2a and 2b).
Figure 3.5: Tumor growth in nude mice.
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3.3 H&E staining
3.3.1 Primary tumor histology
Histologically, the original tumor was an urothelial carcinoma with microscopic inva-
sion of the muscularis propria layer and perivesical fat (pT3a). The malignant cellular
features of this bladder tumor included high nuclear-to-cytoplasmic ratio, nuclear atypia
and presence of mitotic figures. Figure 3.6 shows representative sections of the primary
tumor stained with hematoxylin and eosin.
a (x20) c (x100)
b (x20) d (x400)
Figure 3.6: High grade invasive urothelial carcinoma showing nest of neoplasic cells in-
filtrating through the muscularis propria and perivesical fat of the bladder (a and b).
Presence of lymphovascular space invasion (c) and atypical cells with high nuclear grade
(nuclear atypia and hyperchromatic nuclei with marked anaplasia) and mitotic figures (d).
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3.3.2 Xenograft histology
The histological analysis of the established xenograft revealed a tumor with cellular
characteristics identical to those observed in the primary invasive urothelial tumor of the
bladder as shown in the figure 3.7. In addition to the neoplasic cells, the xenograft also
has a layer of epithelial like cells covering the tumor and in the wall of the cyst as shown
in the figure 3.8. The vesicle-like sac is composed by an epithelial lining layer of variable
number of cells and dense connective tissue.
a (x20) c (x100)
b (x40) d (x100)
Figure 3.7: Micrograph of the tumor developed after xenograft, composed by nests of
neoplasic cells (core) and desmoplastic stroma covered by a layer of epithelial cells (a
and b). Neoplastic cells of moderate to large size with modest amounts of eosinophilic
cytoplasm and nuclear atypia (b and c).
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a (x20) c (x40)
b (x100) d (x400)
Figure 3.8: Micrographs of vesicle-like sac developed by the mouse after xenograft. This
structure is composed by an epithelial lining layer of variable number of cells and dense
connective tissue (a and b). The degree of nuclear atypia varies along the epithelial layer,
having regions with large, hyperchromatic nuclei (c). The cells along the epithelial layer
are bigger in the surface and have largest nuclei (d).
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3.4 Immunohistochemistry
3.4.1 CD147 immunohistochemistry staining
The immunoreactivity to EMMPRIN or CD147 was observed in invasive urothelial
bladder carcinoma cells of the primary tumor and in the tumor cells of the xenograft
as shown in the figure 3.9. Positive immunoreaction was localized in the cytoplasm and
membrane as it was expected due to the properties of the protein being analyzed.
a (x20) c (x40)
b (x40) d (x100)
Figure 3.9: Primary invasive urothelial carcinoma (a and b) and xenograft (c and d) CD147
immunohistochemistry staining demonstrating citoplasmatic and membranar expression.
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3.4.2 P53 immunohistochemistry staining
The protein p53 displayed nuclear expression in both primary and mouse tumor as
shown in the figure 3.10. The primary urothelial carcinoma showed an heterogenic p53
staining pattern, having areas with more nuclear staining than the others. In the case of
xenograft the percentage of stained nucleus was slightly higher than in the primary tumor,
suggesting a more aggressive phenotype.
a (x40) c (x40)
b (x100) d (x100)
Figure 3.10: Primary invasive urothelial carcinoma (a and b) and xenograft (c and d) P53
immunohistochemistry staining demonstrating nuclear expression.
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3.4.3 p63 immunohistochemistry staining
Expression of p63 in primary and mouse tumor specimen was present only in the neo-
plastic cells both in the primary tumor and in the xenograft as shown in the figure 3.11.
Staining was always nuclear and were strong and diffuse both primary and mouse tumor.
Although mouse tumor specimen showed some background staining, no staining was seen
on smooth muscle cells, adipocytes or connective tissue.
a (x20) c (x20)
b (x100) d (x100)
Figure 3.11: Primary invasive urothelial carcinoma (a and b) and xenograft (c and d) p63
immunohistochemistry staining demonstrating diffuse nuclear staining.
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3.4.4 Ki 67 immunohistochemistry staining
Diffuse and heterogenic immunoexpression of Ki 67 was observed in the nucleus of
both human invasive high-grade carcinoma and mouse tumor as shown in the figure 3.12.
However the number of positive cells seemed slightly higher in the xenograft than in the
primary tumor.
a (x20) c (x20)
b (x20) d (x100)
Figure 3.12: Primary invasive urothelial carcinoma (a and b) and xenograft (c and d) Ki67
immunohistochemistry staining demonstrating heterogenic and diffuse nuclear staining.
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3.4.5 Citokeratin 20 immunohistochemistry staining
Citokeratin 20 expression has been described as an objective marker of the neoplastic
change of urothelial cells. In the case of urothelial cells, the expression of CK20 is classified
as normal when the expression is restricted to superficial (umbrella) cells and aberrant
when there is cytoplasmic expression on urothelial cells, other than superficial umbrella
cells. Both primary and mouse tumors showed an abnormal CK20 expression, being CK
20 positive in the full thickness of the tumor as shown in the figure 3.13.
a (x20) c (x40)
b (x100) d (x40)
Figure 3.13: Primary invasive urothelial carcinoma (a and b) and xenograft citokeratin 20
immunohistochemitry staining showing difuse membranar/cytoplasmatic staining of tumor
cell in the first case, and both tumor and epithelia cells in the second case (c and d).
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Chapter 4
Discussion
Unpredictable outcomes from empiric therapy in patients with invasive urothelial blad-
der cancer submitted to radical cystectomy is a widely recognized and frustrating problem
for patients, their caregivers, and medical professionals. There has been a long-standing
hope that new markers and approaches could be used to optimize therapy for each patient.
With this project we aimed to establish an urothelial cancer xenograft model in nude
mice from a sample of invasive urothelial carcinoma, characterize it, and assess the feasibil-
ity of this model for chemotherapy sensitivity and resistance testing. By transferring fresh
tumor fragments directly to nude mice, we successfully established 1 (11%) invasive urothe-
lial cancer xenograft out of 9 trials. The resultant tumor consisted in a high grade solid
tumor with cyst (fluid-filled sac) formation and cellular structure similar to the invasive
urothelial carcinoma of the bladder of the donor patient. This xenograft was successfully
passed to other mice (2/3), at least once.
Comparing with other studies, our success rate for xenograft establishment was lower
[92]. Russell and colleagues reported that 11 of 20 specimens of bladder cancer have grown
as primary implants in nude mice. The variation between success rates may be due to
the different stage and grade of tumors implanted, the animal used or the volume of the
fragment implanted (1 × 2mm3, in our case). Considering the volume of the fragment
implanted, small tumor volume is considered better for obtaining necessary oxygen and
nutrient supplies by passive diffusion before the acquisition of a new blood supply, however,
the number of surviving cells needed for regrowth may be superior in large blocks than in
small ones. The dimensions of the fragment may also influence the lag period.
The latency period (lag period), time between transplantation and first positive evi-
dence of tumor growth, was 4 months for the first generation xenograft, and became shorter
on the subsequent passage, 5 weeks. The long lag period observed for the first case might
be explained by a low fraction of clonogenic cell present in the original tumor, and the
need to adapt and growth in a new environment. Xenografts’s growth rates were different
between the first and second passage, however, until now, it was identical between the
two xenografts in the second passage. Previous studies with human tumor mouse models
reported occurrence of kinetic changes in the human tumor cells after transplantation and
passage in the nude mice [99]. Most frequently, the transplanted tumor adapted to growth
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in animals has a shorter doubling time than the original tumor isolated from a patient.
Growth rates increase further during subsequent passages. The vascularity of the primary
and transplanted tumor also differ, with transplanted tumors showing better blood supply
and less necrosis. This difference could be due to selection of the most rapidly growing
cells from a heterogeneous primary animal, secretion of paracrine growth factors (which
induce neovascularization), or simply tumor size. The development of a fluid filled sac
associated with the first xenograft may also contribute to the differences between growth
rates. Volume change may be influenced by an increase in the fluid quantity, and not only
by the tumor cell population, as it was expected. The consistency and reproducibility of
tumor growth are important factors that will determine the utility of this model. This
parameters will be carefully analyzed and compared in subsequent passages.
The tumor take rate and stability of the tumor in each passage are also important factors
because it enables one to prepare sufficient numbers of xenografts to perform an assessment
of chemotherapeutic drugs sensitivity and resistance. High tumor take rate and stability
in passage will allow the correlation between growth delay after chemotherapy with the
antitumoral activity of the drugs and exclude the influence of individual variance between
xenografts.
There are many local factors that could influence cell growth and morphology of
xenografts, including cell-to-cell and cell-to-matrix interactions, growth factors, cytokines
and hormones. That is the reason, why it is important to perform drug testing only in
the third tumor passage, allowing the substitution of the original tumor stroma, by host
supporting cells. The microenvironment of the tumor–host interface is involved in many
processes impacting on tumor development, including angiogenesis, growth, dissemination
and metastasis of tumors. The crosstalk interaction between tumor cells and adjacent
stromal cells participates in tumor immune escape, spreading and angiogenesis, which is
conducted by a number of soluble and membrane molecules, including emmprin [118].
Histologic and immunohistochemical analysis suggest that xenografts retain their orig-
inal morphology and phenotype, at least during xenograft establishment.
The consistency of the histological and immunohistochemical patterns seen in the orig-
inal tumor and in the xenograft supports the value of this model for drug testing, however,
comparison of this patterns with those of subsequent passages are required. If there is
maintenance of morphologic and biochemical characteristics of the original tumor by the
xenografts, it is expected that chemosensitivity would be similar in both the original and
the xenografted human tumor, and that this correlation would be predictive for both active
single agents and active drug combinations. Future results will give evidence concerning
the local invasion and metastatic potential of tumor in mice.
In the present study, we examined the expression of CD147, P53, p63, KI-67, and
CK20 in primary invasive urothelial carcinoma of the bladder and established xenograft.
We found that CD147 was diffusely expressed in the cytoplasm and membranes of tumor
cells both in the original and xenograft specimens. This molecular marker may be one of
the major criteria to select patients that would benefit of the use of these animal model
to access tumor sensitivity and resistance. CD147 expression has been described as a
strong independent prognostic factor for response and survival after cisplatin-containing
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chemotherapy in patients with advanced bladder cancer.
The other markers of proliferation(Ki-67) and aggressiveness (p53, p63 and CK20) ana-
lyzed were also highly expressed in both primary and xenograft tumors, with no significant
differences between them. The slight increase in the expression of p53 and ki-67 seen in
the xenograft when compared with the primary tumor may reflect a tendency to select of
the most rapidly growing cells from a heterogeneous primary animal during engraftment.
However, further studies are needed to evaluate if it is an isolated case or a tendency and
if this alteration is statistically significant.
The cell line MCR failed to grow when inoculated (1 × 107) in the nude mice. It will
be necessary to inoculate higher quantities of cells to access the tumorigenic potential of
this cell line in nude mice.
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Chapter 5
Conclusion and future work
In conclusion, we were able to establish a direct human cancer xenograft model, that
preserves the main biological characteristics of the original tumor, and may be useful to
evaluate tumor sensitivity and resistance to chemotherapy in patients. The assessment
of chemotherapy sensitivity and resistance of specific tumors will offer the potential of
selecting cancer treatments based on responsiveness of individual tumors and use effective
agents while sparing unnecessary ones, improving patient’s outcome. However further
studies will be necessary to optimize and validate this model. In terms of procedures,
it will be necessary optimize standardize immunostaining reagents and techniques. The
antibodies used for immunohistochemical analyzes were not validated for use in mouse
specimens, as some of them have been obtained from mice. To overcome this limitation
and validate the procedure, we made negative controls, however some background is still
present.
In future work, it will be necessary to identify the profile of the patients that would ben-
efit from this kind of drug testing. This objective can be achieved through the identification
of molecular markers associated with sensitivity or resistance to the main chemotherapeutic
drugs used to treat invasive urothelial bladder carcinoma, in the attempted to prospectively
select individualized chemotherapy.
In the future, this model may also be used to develop preclinical studies with new drugs
in order to identify new therapeutic protocols for resistant tumor to current drugs.
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